Articles related to TRAUMATIC BRAIN INJURY (TBI)

A plasma p-tau217/Aβ42 ratio accurately identified amyloid-PET positivity in older veterans without traumatic brain injury, but diagnostic performance declined substantially among those with a history of TBI, particularly following more severe injuries.

Although ketamine has historically been avoided due to concerns about increased intracranial pressure (ICP), more recent evidence has challenged this assumption.

Risk for CTE is increased with repetitive head impacts sustained during contact sports. However, prior studies have indicated that several neurodegenerative and cerebrovascular pathologies can result from repetitive head impacts.

The multidisciplinary guidelines introduce blood-based biomarkers as key diagnostic tools, potentially reducing unnecessary CT scans while improving outcome predictions.

Amantadine emerges as the pharmacologic agent with the most support for improving cognitive impairment after TBI, while cognitive rehabilitation interventions demonstrate substantial evidence for enhancing neurocognitive function and reducing functional limitations.

Despite the potential benefits of ketamine in treating a range of neurological and psychiatric disorders, the FDA has issued warnings about the potential risks associated with its use, emphasizing the need for careful prescription and clinical oversight.